Oh duh! I see that the prescribing info meant that both dac and led have many interactions with OTHER drugs.
I was thinking it meant they have many interactions with EACH OTHER.
Anyway, I am still unclear on the subject of whether dac and led have interactions with each other. I cannot find any information which suggests that they do. I also cannot find any evidence which proves that they don't. I want to know if the concentration of either drug will be lowered by the presence of the other during a switchover from led to dac, while keeping sof the same?
Possibly this is still one of the many as yet unanswered questions about using the DAAs.
Dac and Led interactions
7 years 11 months ago #6394
I suspect there is little research on what you are asking as:
- It would require crosslabel trials which tend to be expensive.
- the standard treatment approach seems to be to use one NS5A inhibitor thoughout treatment and if that treatment fails to retreat preferably using another NS5A inhibitor that expresses itself via a different path if such an drug exists. This would apparently reduce any risk of resistance effecting the retreatment. I don't know whether Dac and Led differ sufficiently to do that or whether they are entirely analogous.
I'm not a scientist just an interested reader so the above is just my take on it.
G3a since '78 - Dx '12 - F4 (2xHCC)
24wk Tx - PEG/Riba/Dac 2013 relapsed
24wk Tx - Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx - 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 - 22/06/17 UND
SRV12 - 27/07/17 UND
SVR24 - 26/10/17 UND